New Rx instructions tighten use of controversial Alzheimer’s disease drug
Jul 08, 2021
Major changes to prescribing instructions are rare, especially so soon after approval; it change could curb the drug’s use.
More news for Wednesday, May 4
By
Kimberly Bonvissuto
May 04, 2022
Occupancy trends up after omicron slump: Omega … AHCA / NCAL launches Diversity Executive Leadership Program … How to support older adults related to gun ownership decisions, suicide prevention …...
Home Care briefs for Wednesday, June 16
By
Diane Eastabrook
Jun 16, 2021
Acclivity Health and Vytalize Health partner on plan to improve care for palliative care patients … Alzheimer’s Association endorses FDA approval of Aduhelm, criticizes drug price … PACE growth is...
More news for Friday, April 8
By
Kimberly Bonvissuto
Apr 08, 2022
CBRE Seniors Housing & Care Investor Survey identifies industry trends … Senior housing staffing shortages move from severe to moderate: NIC … CMS finalizes Medicare coverage policy for Alzheimer’s...
Few older adults knowledgeable about aducanumab for Alzheimer’s disease
Feb 25, 2022
Less than one-quarter of older adults report they would want to take aducanumab (Aduhelm).
Ethical considerations explored for aducanumab in Alzheimer’s disease
Nov 19, 2021
Grounds are insufficient to offer aducanumab (Aduhelm) for moderate, advanced Alzheimer’s dementia or for individuals without biomarker evidence of brain ß-amyloid, according to a position statement.
Expert panel publishes first recommendations on appropriate use of Alzhemier’s drug Aduhelm
By
Kimberly Bonvissuto
Jul 27, 2021
A panel of experts in the Alzheimer’s field this morning published the first recommendations for the appropriate use of aducanumab (Aduhelm), the controversial new drug to treat early, mild disease.
ARIA described from clinical trials of aducanumab for Alzheimer’s disease
Dec 10, 2021
Amyloid-related imaging abnormalities-edema seen on brain MRI was the most common adverse event in participants receiving high-dose aducanumab (Aduhelm).
FDA head asks for investigation into Alzheimer’s disease drug approval
Jul 12, 2021
The request follows reports that Biogen and the FDA held off-the-books meetings before the drug’s approval that may have violated FDA protocol.
Senate committee backs Califf nomination to head FDA
Jan 14, 2022
Among those who voted against Califf’s nomination were Democrats who expressed concerns about his links to pharmaceutical companies.